Latest news

Latest News / Forthcoming Events / Previous Events (Scroll down to view all sections)
(15/4/2008)

Envision’s Founder and President, Dan Donovan, selected as one of PharmaVOICE’s Top 100 for second year running

Dan Donovan, Founder and President of Envision Pharma, is once again selected as one of PharmaVOICE’s 100 Most Inspiring People in the Life-Sciences Industry. Dan, with his fellow nominees, is featured in the July/August 2008 issue of PharmaVOICE.

The PharmaVOICE 100, now in its fourth year, identifies the key global thought-leaders across the life-sciences industry. The list celebrates the men and women of the industry who inspire and motivate—good people who are doing great things. PharmaVOICE believes that these forward-thinking individuals are setting the standard for corporate leadership, entrepreneurial vision, technology enhancement, marketing strategies, and creative thinking; in many cases they are creating whole new business areas as well as steering their companies to new heights.

The 2008 list reflects not only an individual’s accomplishments but also his or her contribution to the industry as a whole and influence on the growth and well-being of the life-sciences community. The selection process is based on the number of nominations received from individuals who have been motivated or inspired by the industry’s leaders and on other criteria, such as nominees’ work within the community or charitable activities. In essence, PharmaVOICE is recognizing the 100 men and women that it believes are "committed to doing the right thing for the right reasons."

The PharmaVOICE 100 is divided into different categories. After his inclusion in last year’s ‘Risk Takers’ group, Dan has been selected in this year’s ‘Entrepreneurs’ category, which recognizes innovative, forward-thinking leaders who not only carved out a niche in the life sciences—in some cases creating a whole new business area—but also successfully brought their companies to new heights.

Each year, PharmaVOICE strives to give readers a more personal insight into the Top 100; this year it asked the selected industry leaders to provide two adjectives that they believed best described themselves; unsurprisingly, Dan’s were ‘competitive’ and ‘family oriented’.

"I am truly honored to have made the list for the second consecutive year. Once again, I believe my inclusion reflects the efforts of the people on my team who help make our vision a reality. I firmly believe that this honor belongs to all members of the Envision Pharma team" said a delighted Dan.

The PharmaVOICE website includes podcasts featuring the 100 thought leaders. Dan’s individual profile provides an overview of the man, his accomplishments, and his unique leadership style. The article includes a synopsis of Dan’s career before founding Envision Pharma and captures the essence of the Envision environment—a winning environment that has landed the company as a Connecticut Best Places to Work 2 years in a row, first in 2007 as the 2^nd best place and second in 2008 as the best place.

Dan Donovan would once again like to thank PharmaVOICE and the readers who nominated him.

Dan Donovan, Founder and President of Envision Pharma, highlights journal articles that identify good publication practices in recently launched industry website The Publication Plan

It’s no secret that reporting in the general media can be negative towards the pharmaceutical industry. For example, a recent article in the BMJ asked `..is there an (unbiased) doctor in the house?` Unfortunately, this reflects the current views of many people in the media on the industry and medical publications, particularly on the subject of ghostwriters and guest authors.

So it is critical that attention is, where possible, directed towards understanding the work of those who support good publication practices and positive efforts to improve medical writing. In the latest issue of online newsletter The Publication Plan, Dan Donovan of Envision Pharma highlights a number of recent journal articles that provide an alternative point of view on publications planning, and which stress the positive efforts being made in the area of the medical writing. For example, with regard to guest authors, a recent editorial in Nature Biotechnology points out that pharmaceutical research is a team effort, so it is hardly surprising that some people conduct the research, whilst others write the papers. While the article supports some criticisms of the use of ghostwriters, it suggests that ‘crackdown’ recommendations go too far. It concludes that highlighting the issue of ghostwriters to imply that all industry research is somehow unreliable is not helpful.

Dan Donovan is a proponent of positive solutions that respect the roles of the various parties involved in medical publications, including the pharma industry and agencies, publishers, journal editors, and academia, and is a strong advocate of positive change in the medical publications arena. To this end, he has proposed the establishment of a ‘Medical Publishing Cooperative’ with the aim of getting the different stakeholders to understand each others` roles and points of view in an effort to establish best practice in medical writing.

www.ThePublicationPlan.com was launched in July 2008, and is a freely accessible online resource for everyone involved in publication planning, including medical journal editors and publishers, as well as medical writers, communications professionals, and pharmaceutical industry managers. Links to the full articles identified by Dan Donovan are available in the Commentary section and can be accessed by subscribers to the newsletter.

Dan Donovan and Envision Pharma lead the way for the founding of a Medical Publishing Co-operative – from an interview with Faith Reidenbach for the American Medical Writers Association Journal.

When Envision Pharma Founder and Managing Director Dan Donovan presented a poster entitled “The Dangers of Polarization in Publications” to the 2007 national conference of the American Medical Writers Association, he expressed concern that key stakeholders in medical publishing are continuously becoming more biased and extreme in their positions on disputed issues. His solution: to establish a Medical Publishing Co-operative from an international array publishers, editors, writers, representatives from the medical and pharmaceutical industries, as well as legislative representatives and representatives from the National Institutes of Health, with the aim of bridging the divide “characterized by mistrust and misperceptions.

“You need to understand other people’s roles and their professions before you start casting aspersions,” he explains. “We all have an interest in generating fairly balanced publications. Instead of perpetuating an ‘us-against-them’ attitude, we can seek cooperation.”

Transparency of the biases which color and shape all aspects of the publication process will be a hallmark of the co-op. “The problem is a lack of understanding. It’s important to remember that writing assistance doesn’t come solely from the [medical writing] industry. Many major academic institutions have writing staff which, like us, are subject to potential biases. Investigators in academia need to get published in order to get grants, promotions, and so forth. Admitting that everyone has their own set of biases, and understanding what those biases are, will be another way the co-op could help.”

Proving his commitment to the understanding of which he speaks, Donovan proposed the idea at the Blackwell Publishing annual meeting. The concept was surprisingly well received, with only two naysayers in an audience of about fifty. Encouraged, the Envision Pharma founder has extended an open invitation: “I’d like anyone who has a view, whether it’s similar to mine or the polar opposite, to contact me and talk about it. This way we can begin to move the idea forward.”

Envision Pharma has offices in Horsham, UK; Southport and Glastonbury, Connecticut, USA; and Philadelphia, Pennsylvania, USA. If you would like to learn more about Envision Pharma or any of our solutions, please contact Dan Donovan at dan.donovan@envisionpharma.com or 1-203-480-0090 or Joe Brown at joe.brown@envisionpharma.com or 1-860-721-0810.

Envision Pharma’s Dan Donovan and Thomas Gegeny clarify the need for professional medical writers as defined by the International Society for Medical Publishing Professionals position statement: the role of the professional medical writer.

When the International Society for Medical Publishing Professionals (ISMPP) issued their position statement on the role of the professional medical writer, they sought to defend medical writers as “an important and valuable resource in contemporary clinical research,” and to assist in raising the profession’s profile and credibility through the endorsement of the “contributorship model, which offers detailed information on the roles of all who participated in planning, conducting, developing, and publishing medical research.”

Aware that the role of the medical writer is often misunderstood at best and, at worst, actively disparaged, ISMPP points to the varied and often exceptional backgrounds many of these professionals bring to their collaborations with the designated authors of scientific or clinical manuscripts; in addition to their excellent communication skills and a more practical knowledge of the needs of the medical publishing industry (such as style, format, and disclosure guidelines), many medical writers will have years of experience with pharmaceutical companies or medical communications agencies, possess advanced degrees in the life sciences, or even be physicians themselves.

Envision Pharma’s Managing Director Dan Donovan and senior medical writer Thomas Gegeny recognize ISMPP’s definition of the industry professional, and urge the Society one step further: to illustrate “the dire need and practical justification for qualified professional medical writers.”

The pair list increased demand for clinical trials, both for regulation and safety assurances, legislative initiatives, and their resulting strains on the time and resources needed for accurate recording and reporting of results, as evidence of the growing need for “skilled professionals to assist in the dissemination of important scientific and clinical findings.”

For their part, ISMPP concurs with Donovan and Gegeny, stating “that was…the foundation on which the [position statement] was based.”

“The ‘climate of mistrust’ of medical writers,” write Donovan and Gegeny in Current Medical Research and Opinion (2007; 23; XX), “can only be overcome when the case is made (and accepted) for their legitimate role, in addition to endorsing transparent disclosure of their involvement.”

Envision Pharma Acquired by Leading Evidence-Based Medicine Company

Envision Pharma today announced their acquisition by United BioSource Corporation (UBC). UBC provides evidence-based solutions to support the development and commercialization of pharmaceuticals, biotechnology, and medical devices. The acquisition of Envision Pharma expands the company’s global presence and capability in the development and delivery of scientific communication.

Envision Pharma has two market-leading applications. Datavision™ is the pharmaceutical industry’s premier application for developing and managing transparent, compliant publications programs. Used by over 30 companies with nearly 400 products, Datavision™ provides a platform for strategic planning and workflow management, while ensuring compliance and precision in the publications process. Visiontracker™, launched in 2007, offers management of independent investigator trials, supporting the process from application through to study completion for both the investigator and sponsor.

Envision Pharma combines its publications technology software with a global staff of experienced medical writers to support the planning and development of medical publications and other scientific communications for its pharmaceutical clients. The team also provides publication consultancy services to the industry, including the development of policies and processes that ensure optimal legislative and guideline adherence.

“We are thrilled to welcome the Envision team to the UBC family,” says Ethan Leder, CEO of UBC. “Like UBC,” Leder continues, “Envision combines strategically driven scientific and technology solutions for life sciences clients. Given the increasing demand of regulators and public opinion for transparency in research, Envision’s contribution to the production of objective, scientifically driven medical publications is a cornerstone of our evidence-based credo and highly valuable to the entire medical community.”

“Joining UBC helps us achieve our vision of bringing a more robust scientific offering to our clients faster than we could have on our own, with people of a similar mindset,” notes Brian Hepburn, Envision Co-founder and General Manager.

"UBC’s mission to build all of its services with a focus on evidence made UBC an ideal partner for Envision,” says Dan Donovan, Envision Co-founder and Senior Vice President of Strategy and Market Development. Dan Donovan adds, “Envision’s mission is built around the notion that products developed with a solid evidence base will deliver the greatest impact and success for all stakeholders, from industry to healthcare and insurance providers, governments, and patients.”

Envision Pharma is an innovative scientific communications and technology company providing commercially focused, strategically driven scientific and technology solutions to the pharmaceutical, biotechnology, and device industries. Envision specializes in data dissemination and the effective application of smart technology. For further information on Envision Pharma visit www.envisionpharma.com.

United BioSource Corporation (UBC) is a global pharmaceutical services organization that helps emerging and established life science companies develop and commercialize medical products. UBC specializes in providing new and innovative ways to study drugs and devices by offering expertise in science, strategy, and execution.

ENVISION PHARMA of Southport named Connecticut’s

“Best Place to Work…”

An independent survey of companies from across the state of Connecticut has named Envision Pharma, a medical and scientific communications company based in Southport, as the state’s “Best Place to Work.” The survey was conducted by the Best Companies Group of Harrisburg, Pennsylvania, with the results being compiled and ranked by the Wilmington, Delaware, firm ModernThink, LLC.

Monday’s announcement of the award marked the second time the young company made the list – they took the Number Two spot in 2007. “After serving as bridesmaid [last year],” says company co-founder and managing director Dan Donovan, “this award provides validation that we are really doing something right.”

Gail Lebert of the Hartford Business Journal, sponsors of the survey, noted that Envision’s win demonstrates how “success in business is more than a matter of products, branding and service. It’s also about the character of the organization as reflected in the contentment of its employees.”

The survey looked at each company’s personnel policies and practices, demographics, and communication, as well as using a 65-point employee questionnaire to assess leadership development, fairness, and effectiveness of collaboration. Envision Pharma, based in Southport with a second Connecticut office in Glastonbury, as well as offices in Philadelphia and the United Kingdom, came up tops across the board.

Their success isn’t accidental. As Donovan explains, the young company’s success and marked growth makes them a target for headhunters. To combat this, Envision works hard to foster employee loyalty. Company benefits, including full medical and dental coverage, serve to let ‘Envision-aries’ know their value to the company.

On a more day-to-day level, the company doesn’t get hung-up on titles. “[We] don’t believe any one person is more valuable than the next,” says Donovan. “Everybody plays an important role.”

But perhaps most telling of Envision’s commitment to its employees is the way in which their individual passions direct the company’s heart. Since it’s founding, Envision has annually made substantial charitable giving a key element of its character, with a particular emphasis on issues significant to its personnel. In addition to official company support of the Lupus Foundation and the Lindsay Foundation – both organizations which have directly affected the lives of Envision employees and their families – team members routinely reach out to one another and together have raised many tens of thousands of dollars for charities such as AIDS Walk, Relay for Life, and the American Heart Association, to name but a few.

When one employee volunteered to shave his head for the St Baldrick’s Foundation (supporting families battling childhood cancer), the company not only offered to match funds, but also showed up on the night en masse in a display of solidarity with the ‘shavee’.

“We’ve been able to stay true to our mission,” says a rightly proud Donovan, pointing to his company’s success at both supporting their clients’ needs as well as each other’s. “In my book, that’s the sign of a great team.”

For more information, please contact: Tim Deenihan, Envision Editorial Solutions tim.deenihan@envisionpharma.com or (203) 296-0869

Envision Technology Solutions Selected as 2007 Lilly Global Supplier Award Winner

Envision Pharma is proud to announce its selection as a 2007 Lilly Global Supplier Award winner. Nominated companies are those that Eli Lilly and Company considers to have had a positive impact on the corporate priorities of Lilly by delivering exemplary quality, service, speed, cost reduction, and other valuable contributions.

Envision Pharma is honored to have been selected as 1 of just 12 winners to receive an award by our Lilly colleagues for having exceeded their expectations in the services we provide, a huge achievement in itself as Lilly has approximately 10,000 suppliers globally.

Envision Pharma achieved this recognition following the selection and implementation of the industry leading publications planning software, Datavision™. Well after software implementation, the Envision team continues to provide support through a comprehensive support structure, including a hot line and regular customer care and technology review meetings.

The success of the collaboration is testament to the strong partnership philosophy of both companies. Envision looks forward to working with Lilly and to providing the same level of exceptional service to all of our Datavision clients.

Envision’s Founder and President, Dan Donovan, Selected as 1 of PharmaVOICE’s Top 100 of 2007

Dan Donovan, Founder and President of Envision Pharma, selected as 1 of PharmaVOICE’s 100 Most Inspiring People in the Life-Sciences Industry. Dan, with his fellow nominees, is featured in the July/August edition of PharmaVOICE.

The PharmaVOICE 100 is selected from a spectrum of global thought-leaders across the life-sciences industry. This year’s selection reflects not only each individual’s accomplishments and those of their companies but also each individual’s contribution to the industry as a whole and influence on the growth and well-being of the community and peer-groups. The selection process is based on the number of nominations received from individuals who had been motivated or inspired by them and on other criteria, such as nominees’ work within the community or charitable activities.

The PharmaVOICE 100 is divided into different categories. Dan was fittingly honored in the “Risk Takers” category; this group is composed of individuals with an innovative approach who are helping to redefine the life-sciences industry by improving technology, processes, and services.

"I was both surprised and honored to have been selected to the Top 100. I believe my inclusion is more about the people on my team who help make our vision a reality than it is about anything that I do single-handedly. The honor belongs to all of us” remarked Dan Donovan.

Dan’s PharmaVOICE profile provides a overview of the man, his accomplishments, and his unique leadership style. The article includes a synopsis of Dan’s career before founding Envision Pharma and captures the essence of the Envision environment.

Dan would like to thank PharmaVOICE and the readers who nominated him.

Pharmafocus (May 2007)

Envision Pharma’s Dan Donovan on the Changing Face of Medical Education

Dan Donovan, Envision Pharma’s Founder and President, was invited to comment on the changing face of medical education in the June Issue of Pharmafocus, a leading monthly publication that provides timely news articles of national and international interest to the UK pharmaceuticals industry and is published by Wiley Pharmafile Ltd.

In the article “The Changing Face of Medical Education,” Dan Donovan answers some topical

questions: Is medical education the new PR? Will the supply of key opinion leaders ever dry up?

and, Can you measure medical education’s return on investment?

To read the full article on the Pharmafocus website, please click on the link below.

http://www.pharmafocus.com/cda/focusH/1,2109,22-0-0-JUN_2007-focus_feature_detail-0-491284,00.html

Technology and Process Come Together – A Global Publication Management Case Study for a Major Pharmaceutical Company

Driven by a need to improve its overall publication track record and ability to communicate medical information, along with a need to standardize and improve publication management processes, a major pharmaceutical company had committed to a complete transformation of global publication management processes, technology, and organization. For this critical effort, BusinessEdge Solutions, an industry-focused business and technology consulting firm, teamed with Envision Pharma, a leading provider of scientific communications and technology solutions to transform the client’s publication processes.

BusinessEdge Solutions addressed process design and change management working closely to align with and leverage the functionality of Datavision^TM, Envision Pharma’s industry leading web-based software application designed specifically for the pharmaceutical industry to improve efficiency in data planning, management, and dissemination. BusinessEdge devised and conducted a rapid workshop-driven approach for developing and validating a new global publication process enabled by Datavision^TM. BusinessEdge also assisted the client in defining publication team roles and responsibilities, identifying and addressing change issues for successful implementation, and managing the necessary communications.

A complete case study describing this work will be available at the BusinessEdge Solutions Booth 754 at the 43^rd Annual DIA Meeting in Atlanta, GA; June 17– 20.

For further information about BusinessEdge Solutions, visit www.businessedge.com. For further information about Datavision or Envision Pharma, please contact Joe Brown at joe.brown@envisionpharma.com or (860) 266-4949 or Dan Donovan at dan.donovan@envisionpharma.com or (203) 480-0090.

Envision Pharma Announced New Philadelphia Office – Summer 2007

Envision Pharma, a leading medical and scientific communications company providing commercially-focused, strategically-driven, scientific and technology solutions to the pharmaceutical and biotechnology industries, was pleased to announce the opening of its third office in the USA.

Envision Pharma opened its new office in Philadelphia, PA, in the summer of 2007. The new Philadelphia office offers the same commercially-focused, scientifically-driven medical communications as the teams currently based in Southport, CT, and Horsham, UK, to the US domestic and global markets.

With two teams based in North America, and one team based in Horsham, UK, Envision is expanding its ability to provide round-the-clock service, ensuring that we meet deadlines even at short notice, and working as a natural extension of the client’s product team, with experience in most therapeutic areas.

Envision are still recruiting for the new office. All open positions are currently posted on the Website. So, if you are at the top of your field, seeking a challenging position and the rewards that come with it; if you want to work for a company that is growing and are interested in working with the best people in the industry, check the Careers Section of our Website (http://www.envisionpharma.com) regularly for upcoming opportunities.

Envision Pharma named one of the top 2 “Best Places to Work in Connecticut” – 2007

On April 10, Envision learned its placement as one of the top 2 of 25 “Best Places to Work in Connecticut – 2007,” based upon the company’s policies, procedures, benefits, and determination to continually improve the employee experience.

The “Best Places to Work in Connecticut” is a state-wide program managed by the Best Companies Group; this prestigious and exciting initiative is dedicated to finding and recognizing Connecticut’s best employers, specifically companies demonstrating workplace excellence.

The Best Companies Group, in partnership with ModernThink, LLC, researches the dynamics and characteristics of the workplace and by analyzing the data produces a “Best Places to Work” distinction. The very mission of their organization is to "identify and recognize" organizations that are leading the way in defining the employee experience of the 21st century.

“I am really pleased that we have been recognized as one of the Best Places to Work in Connecticut. Brian Hepburn and I worked hard from Day 1 to create a culture that attracts the best people and, perhaps more importantly, encourages them to stay,” commented Dan Donovan, Envision Pharma’s Founder and President. “We wholeheartedly believe that happy team members are much more productive and loyal. That satisfaction is then reflected in the solutions we provide to our clients. We will continue to develop the skills and talents of our scientific solutions and technology solutions team members in a manner that creates an environment that allows excellence to flourish.”

If you would like to learn more about working for Envision Pharma in our Southport or Glastonbury, Connecticut, offices, please contact Cynthia Kabbe at cynthia.kabbe@envisionpharma.com. If you would like to learn more about working for Envision Pharma in the United Kingdom, please contact Fiona Voice at fiona.voice@envisionpharma.com.

Visionlearning Rolled Out Enterprise Wide

Following the successful launch of Envision Pharma’s Continuing Medical Education (CME) grant management software solution, Visionlearning^TM, specifically developed to carefully manage and document your grant application and approval process, Envision Pharma were pleased to announce achievement of another company milestone, the enterprise-wide implementation of this solution at a major international pharmaceutical company.

The allocation of educational grants by the pharmaceutical industry is undergoing close scrutiny by regulatory authorities and governments. Key aspects being scrutinized include:

The role of marketing personnel in the decision process of grant allocation.
The size of grants being allocated and the proportion of physician/patient organization’s funding that these grants comprise, and thereby their reliance on Pharma company grants.
The use of grants to overtly develop key opinion leaders as advocates for a pharmaceutical product, and to influence physicians.
The use of grants to directly or indirectly develop publications or materials that promote a pharmaceutical product.

The need to carefully manage and document your grant application and approval process has never been more pressing, which is why Envision Pharma has developed Visionlearning^TM.

Visionlearning^TM is an integrated software solution that allows companies to manage and track their complete educational grant program across a single product, multiple products, multiple therapeutic areas, or the entire enterprise. With Visionlearning^TM, facilitation of the grant management process is consistent, transparent, and auditable.

If you would like to learn more about Envision Pharma, Visionlearning^TM or any of our solutions, please contact Dan Donovan at dan.donovan@envisionpharma.com or 1-203-480-0090 or Joe Brown at joe.brown@envisionpharma.com or 1-860-721-0810.

PREVIOUS EVENTS

October 11-13, 2007

Envision Pharma was a dynamic presence at the American Medical Writers Association’s 67^th Annual Conference: A Legacy of Leadership – Marriott Atlanta Marquis, Atlanta, GA – October 11-13, 2007.

Envision Pharma’s Founder and Managing Director, Dan Donovan, moderated a breakfast roundtable discussion entitled “Measuring Your Success: An In-Depth Discussion of Publications Planning Metrics.” This roundtable was an opportunity for attendees to join their colleagues to exchange ideas, experiences, and insights on publications planning metrics.

Dan Donovan also led an open session entitled “The Journal Selection Process: Getting Beyond the Impact Factor.” This open session covered the multitude of considerations that should inform any decision on submitting work to the appropriate journal—not necessarily the journal with the highest impact factor.

As well as taking charge of the breakfast roundtable and the open session, Dan Donovan contributed a poster entitled “The Dangers of Polarization in Publications,” which was featured as part of the informative and very well received poster display.

Thomas Gegeny, a member of Envision Pharma’s Scientific Solutions team, also was active at the conference. Tom led 2 3-hour workshops: “Effectively Searching Online Databases” and “The Internet: How and Where to Find the Information You Seek.” Tom also organized and moderated an open session featuring Tanja Popovic, MD, PhD, the Chief Science Officer of the Centers for Disease Control and Prevention. Dr. Popovic’s presentation was entitled, “Public Health Challenges in an Era of Global Connectivity and Communication Revolution.” At the meeting, Tom was elected to a second term as secretary of AMWA.

The Envision Pharma Exhibit Booth also was featured at the conference; here attendees were able to acquire in-depth information on Envision Pharma’s technology solutions and view software demonstrations. Envision Pharma representatives were on-hand to discuss individual solutions and answer any questions regarding Envision Pharma or its industry-leading software solutions.

If you were unable to attend this conference but would like to learn more about Envision Pharma or any of our solutions, please contact Dan Donovan at dan.donovan@envisionpharma.com or (203) 480 0090 or Joe Brown at joe.brown@envisionpharma.com or (860) 266 4949.

September 27-28, 2007

Envision Pharma launches Datavision 4.0 at the 2^nd Annual Datavision^TM Industry Forum held in Montreal, Quebec – September 27-28, 2007.

Building upon the success of Envision Pharma’s 1^st Annual Datavision^TM Industry Forum, this year’s forum brought together the growing Datavision™ community from a cross section of industry – large, medium and small, East Coast, Mid West, West Coast and Europe.

Offering a mixture of plenary sessions, a plethora of workshops, interactive information sharing, and fun, the forum was designed to maximize the effectiveness of each Datavision user, demonstrating skills to improve individual and team effectiveness and ways to enrich the client’s enterprise through open communication.

“I enjoyed meeting and working with people from the different groups at Envision and seeing how well they all worked together.”

This year’s forum included time set aside for hands-on learning and sharing of experiences.which provided the perfect venue for the introduction of Datavision^TM 4., Users had the opportunity to hear about the challenges that their peers faced, to contribute their thoughts and ideas on improving business practices, and to participate in the development of future Datavision™ releases.

“I was really impressed. Envision listened to customers and really responded well to feedback.”

If you were unable to attend this forum but would like learn more about Datavision™, the Datavision^TMIndustry Forum, Envision Pharma, or any of our solutions, please contact Dan Donovan at dan.donovan@envisionpharma.com or (203) 480 0090 or Joe Brown at joe.brown@envisionpharma.com or (860) 266 4949.